keyword
MENU ▼
Read by QxMD icon Read
search

HFREF

keyword
https://www.readbyqxmd.com/read/27905877/mineralocorticoid-receptor-antagonists-for-heart-failure-systematic-review-and-meta-analysis
#1
Nicolas M Berbenetz, Marko Mrkobrada
BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) have been associated with improved patient outcomes in patients with heart failure with reduced ejection fraction (HFrEF) but not preserved ejection fraction (HFpEF). We conducted a systematic review and meta-analysis of selective and nonselective MRAs in HFrEF and HFpEF. METHODS: We searched Cochrane Central Register of Controlled Trials, MEDLINE and EMBASE. We included randomized controlled trials (RCT) of MRAs in adults with HFpEF or HFrEF if they reported data on major adverse cardiac events or drug safety...
December 1, 2016: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/27905476/heart-failure-neprilysin-inhibition-attenuates-risk-of-hyperkalaemia-in-hfref
#2
Karina Huynh
No abstract text is available yet for this article.
December 1, 2016: Nature Reviews. Cardiology
https://www.readbyqxmd.com/read/27900610/novel-sgc-stimulators-and-sgc-activators-for-the-treatment-of-heart-failure
#3
Stefanie Breitenstein, Lothar Roessig, Peter Sandner, Kelly S Lewis
The burden of heart failure (HF) increases worldwide with an aging population, and there is a high unmet medical need in both, heart failure with reduced ejection fraction (HFrEF) and with preserved ejection fraction (HFpEF). The nitric oxide (NO) pathway is a key regulator in the cardiovascular system and modulates vascular tone and myocardial performance. Disruption of the NO-cyclic guanosine monophosphate (cGMP) signaling axis and impaired cGMP formation by endothelial dysfunction could lead to vasotone dysregulation, vascular and ventricular stiffening, fibrosis, and hypertrophy resulting in a decline of heart as well as kidney function...
November 30, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27899856/effect-of-spironolactone-on-plasma-apelin-12-levels-in-patients-with-chronic-systolic-heart-failure
#4
Mustafa Topuz, Mehmet Cosgun, Oğuz Akkuş, Atilla Bulut, Omer Sen, Ayşe Nur Topuz, Murat Caylı
BACKGROUND: The aim of this study was to determine whether spironolactone therapy has an effect on serum apelin-12 levels in heart failure with reduced ejection fraction (HFrEF) patients. METHODS: Eighty outpatients previously diagnosed with HFrEF were enrolled in the current study. Included patients were taking only standard heart failure therapy (ST) (angiotensin converting enzyme or angiotensin receptor blocker, beta-blockers, loop diuretics and anticoagulant or antiagregan agents) without a mineralocorticoid receptor antagonists (MRA) because of its side effects, and were designated the non-MRA group; those patients taking 25 mg/daily spironolactone in addition to the ST were deemed the MRA group...
November 2016: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/27886615/hfpef-and-hfref-exhibit-different-phenotypes-as-assessed-by-leptin-and-adiponectin
#5
Ulrika Ljung Faxén, Camilla Hage, Anna Andreasson, Erwan Donal, Jean-Claude Daubert, Cecilia Linde, Kerstin Brismar, Lars H Lund
BACKGROUND: Heart failure with reduced ejection fraction (HFrEF) exhibits a "reverse metabolic profile". Whether this profile exists in HF with preserved ejection fraction (HFpEF) is unknown. We tested the hypothesis that HFpEF and HFrEF are similar regarding concentrations of and prognostic impact of leptin and adiponectin. METHODS: In patients with HFpEF(n=79), HFrEF(n=84), and controls(n=71), we analyzed serum leptin and adiponectin concentrations, their correlations, and associations with outcome...
November 9, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27872509/diagnostic-utility-of-ang-in-coronary-heart-disease-complicating-chronic-heart-failure-a-cross-sectional-study
#6
Peng Yu, Ming Liu, Xue Yang, Ying Yu, Ji Zhao, Lei Zhang, Rui Tong, Hong Jiang, Yunzeng Zou, Junbo Ge
Angiogenin (ANG) has been shown to be elevated in several cardiovascular diseases. To detect its levels and diagnostic capacity in coronary heart disease (CHD) patients complicating chronic heart failure (CHF), we performed this cross-sectional study and enrolled 616 CHD patients and 53 healthy controls. According to complicating CHF or not, the patients were divided into CHF group (n = 203) and CHD disease controls (n = 413), in which the CHF group was subdivided as heart failure with reduced ejection fraction (HFrEF) group or heart failure with preserved ejection fraction (HFpEF) group on the basis of left ventricular ejection fraction (LVEF), or as different NYHA class group...
2016: Disease Markers
https://www.readbyqxmd.com/read/27871223/patients-with-hfpef-and-hfref-have-different-clinical-characteristics-but-similar-prognosis-a-retrospective-cohort-study
#7
Tamrat Befekadu Abebe, Eyob Alemayehu Gebreyohannes, Yonas Getaye Tefera, Tadesse Melaku Abegaz
BACKGROUND: Globally, heart failure (HF) has been recognized as one of the major cardiovascular disorder with high morbidity, mortality and considerable social impact. In Sub Saharan African countries, HF has turned out as a leading form of cardiovascular diseases, and has considerable socioeconomic impact. However, there are differences in clinical characteristics and survival status among patients with preserved (HFpEF) and reduced (HFrEF) ejection fraction. The aim of this study is to outline the clinical characteristics and medication profile, assess the survival status and prognostic factors of Ethiopian HF patients with HFrEF and HFpEF...
November 21, 2016: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/27868321/dementia-related-adverse-events-in-paradigm-hf-and-other-trials-in-heart-failure-with-reduced-ejection-fraction
#8
Jane A Cannon, Li Shen, Pardeep S Jhund, Søren L Kristensen, Lars Køber, Fabian Chen, Jianjian Gong, Martin P Lefkowitz, Jean L Rouleau, Victor C Shi, Karl Swedberg, Michael R Zile, Scott D Solomon, Milton Packer, John J V McMurray
AIMS: Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with reduced ejection fraction (HFrEF), as shown in PARADIGM-HF which compared the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan with enalapril. As neprilysin is also one of many enzymes clearing amyloid-β peptides from the brain, there is a theoretical concern about the long-term effects of sacubitril/valsartan on cognition. Therefore, we have examined dementia-related adverse effects (AEs) in PARADIGM-HF and placed these findings in the context of other recently conducted HFrEF trials...
November 20, 2016: European Journal of Heart Failure
https://www.readbyqxmd.com/read/27867532/left-ventricular-ejection-fraction-recovery-in-patients-with-heart-failure-treated-with-intravenous-iron-a-pilot-study
#9
Julio Núñez, José Vicente Monmeneu, Anna Mollar, Eduardo Núñez, Vicent Bodí, Gema Miñana, Sergio García-Blas, Enrique Santas, Jaume Agüero, Francisco J Chorro, Juan Sanchis, Maria Pilar López-Lereu
AIMS: In patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency, treatment with intravenous iron has shown a clinical improvement regardless of anaemic status. Cardiac magnetic resonance (CMR) T2* sequence has shown a potential utility for evaluating myocardial iron deficiency. We aimed to evaluate whether T2* sequence significantly changes after ferric carboximaltose (FCM) administration, and if such changes correlate with changes in left ventricle ejection fraction (LVEF)...
December 2016: ESC Heart Failure
https://www.readbyqxmd.com/read/27867524/varying-effects-of-recommended-treatments-for-heart-failure-with-reduced-ejection-fraction-meta-analysis-of-randomized-controlled-trials-in-the-esc-and-accf-aha-guidelines
#10
REVIEW
Marius Mark Thomsen, Christian Lewinter, Lars Køber
The aim of this paper is to evaluate the treatment effects of recommended drugs and devices on key clinical outcomes for patients with heart failure with reduced ejection fraction (HFREF). Randomized controlled trials (RCTs) listed in the 2012 HF guideline from the European Society of Cardiology as well as the 2013 HF guideline from the American College of Cardiology Foundation and American Heart Association were evaluated for use in the meta-analysis. RCTs written in English evaluating recommended drugs and devices for the treatment of patients with HFREF were included...
December 2016: ESC Heart Failure
https://www.readbyqxmd.com/read/27866868/lack-of-evidence-of-lower-30-day-all-cause-readmission-in-medicare-beneficiaries-with-heart-failure-and-reduced-ejection-fraction-discharged-on-spironolactone
#11
Phillip H Lam, Daniel J Dooley, Chakradhari Inampudi, Cherinne Arundel, Gregg C Fonarow, Javed Butler, Wen-Chih Wu, Marc R Blackman, Markus S Anker, Prakash Deedwania, Michel White, Sumanth D Prabhu, Charity J Morgan, Thomas E Love, Wilbert S Aronow, Richard M Allman, Ali Ahmed
BACKGROUND: Therapy with evidence-based heart failure (HF) medications has been shown to be associated with lower risk of 30-day all-cause readmission in patients with HF and reduced ejection fraction (HFrEF). METHODS: We examined the association of aldosterone antagonist use with 30-day all-cause readmission in this population. Of the 2443 Medicare beneficiaries with HF and left ventricular EF ≤35% discharged home from 106 Alabama hospitals during 1998-2001, 2060 were eligible for spironolactone therapy (serum creatinine ≤2...
November 4, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27865724/leg-lifting-in-hfref-frank-starling-and-mitral-regurgitation
#12
EDITORIAL
Thierry C Gillebert
No abstract text is available yet for this article.
November 10, 2016: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/27863863/effect-of-%C3%AE-2-adrenergic-receptor-stimulation-on-lung-fluid-in-stable-heart-failure-patients
#13
Bryan J Taylor, Eric M Snyder, Maile L Richert, Courtney M Wheatley, Steven C Chase, Lyle J Olson, Bruce D Johnson
BACKGROUND: The purpose of this study was to determine: (1) whether stable heart failure patients with reduced ejection fraction (HFrEF) have elevated extravascular lung water (EVLW) when compared with healthy control subjects; and (2) the effect of acute β2-adrenergic receptor (β2AR) agonist inhalation on lung fluid balance. METHODS: Twenty-two stable HFrEF patients and 18 age- and gender-matched healthy subjects were studied. Lung diffusing capacity for carbon monoxide (DLCO), alveolar-capillary membrane conductance (DmCO), pulmonary capillary blood volume (Vc) (via re-breathe) and lung tissue volume (Vtis) (via computed tomography) were assessed before and within 30 minutes after administration of nebulized albuterol...
October 2, 2016: Journal of Heart and Lung Transplantation
https://www.readbyqxmd.com/read/27860029/different-correlates-but-similar-prognostic-implications-for-right-ventricular-dysfunction-in-heart-failure-patients-with-reduced-or-preserved-ejection-fraction
#14
Stefano Ghio, Marco Guazzi, Angela Beatrice Scardovi, Catherine Klersy, Francesco Clemenza, Erberto Carluccio, Pier Luigi Temporelli, Andrea Rossi, Pompilio Faggiano, Egidio Traversi, Olga Vriz, Frank Lloyd Dini
AIMS: To evaluate whether the clinical and echocardiographic correlates and the prognostic significance of right ventricular (RV) dysfunction are different in heart failure patients with reduced (HFrEF), mid-range (HFmrEF), or preserved (HFpEF) left ventricular ejection fraction. METHODS AND RESULTS: The study included 1663 patients with heart failure caused by ischaemic or hypertensive heart disease or by idiopathic cardiomyopathy. Left ventricular ejection fraction was <40% in 1123 patients (HFrEF), 40-49% in 156 patients (HFmrEF) and ≥50% in 384 patients (HFpEF)...
November 17, 2016: European Journal of Heart Failure
https://www.readbyqxmd.com/read/27858191/focus-on-the-novel-cardiovascular-drug-lzc696-from-evidence-to-clinical-consideration
#15
L M Lin, Y Wu, M F Wu, J X Lin
LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor (ARNI), is comprised of the angiotensin receptor blocker valsartan and the neprilysin inhibitor pro-drug sacubitril (AHU377). After oral administration, AHU377 is rapidly metabolized to the active neprilysin inhibitor LBQ657. LCZ696 exerts its effects of diuresis, natriuresis, vasodilation and aldosterone secretion inhibition through simultaneous renin-angiotensin-aldosterone system (RAAS) blockade and natriuretic peptides system (NPS) enhancement...
November 18, 2016: Cardiovascular Drugs and Therapy
https://www.readbyqxmd.com/read/27858115/-the-new-esc-guidelines-for-acute-and-chronic-heart-failure-2016
#16
C U Oeing, C Tschöpe, B Pieske
The new guidelines for the diagnosis and treatment of acute and chronic heart failure (HF) were presented in May 2016 during the congress of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in Florence. An important amendment affects the classification of HF which now differentiates between HF with preserved ejection fraction (HFpEF) and left ventricular EF (LVEF) > 50%, HF with reduced ejection fraction (HFrEF, LVEF < 40%) and the new entity HF with mid-range ejection fraction (HFmrEF, LVEF 40-49%)...
December 2016: Herz
https://www.readbyqxmd.com/read/27833993/galectin-3-in-children-with-chronic-heart-failure-with-normal-and-reduced-ejection-fraction-relationship-to-disease-severity
#17
Alyaa Amal Kotby, Omneya Ibrahim Youssef, Mohamed Omar Elmaraghy, Osama Salah El Sharkawy
Heart failure (HF) progression has not been studied in pediatric patients as well as HF in patients with a normal ejection fraction (HFNEF). We aimed to evaluate galactin-3 in children with HFNEF and reduced ejection fraction (HFREF) and its correlation to disease severity and progression. This cross-sectional study involved 45 chronic HF patients taking G1a (23 HFNEF children) and G1b (22 HFREF children) compared to 45 age- and sex-matched controls (G2) subjected to history taking, Ross functional HF classification, conventional and tissue Doppler echocardiographic systolic and diastolic function assessment (FS%, E/A, S m, E m/A m, E/E m) and laboratory investigations [glomerular filtration rate, serum galactin-3 level (ELISA)]...
November 11, 2016: Pediatric Cardiology
https://www.readbyqxmd.com/read/27830348/steroidal-and-novel-non-steroidal-mineralocorticoid-receptor-antagonists-in-heart-failure-and-cardiorenal-diseases-comparison-at-bench-and-bedside
#18
Peter Kolkhof, Frederic Jaisser, So-Young Kim, Gerasimos Filippatos, Christina Nowack, Bertram Pitt
Characterization of mice with cell-specific deletion or overexpression of the mineralocorticoid receptor (MR) shed a new light on its role in health and disease. Pathophysiological MR activation contributes to a plethora of deleterious molecular mechanisms in the development of cardiorenal diseases like chronic kidney disease (CKD) and heart failure (HF). Accordingly, the available steroidal MR antagonists (MRAs) spironolactone (first generation MRA) and eplerenone (second generation MRA) have been shown to be effective in reducing cardiovascular (CV) mortality and morbidity in patients with chronic HF and a reduced left ventricular ejection fraction (HFrEF)...
November 10, 2016: Handbook of Experimental Pharmacology
https://www.readbyqxmd.com/read/27824422/-sacubitril-valsartan-in-patients-with-diabetes-and-heart-failure
#19
Vincent Matthias Brandenburg, Hans-Peter Brunner-La Rocca, Nikolaus Marx
Sacubitril / Valsartan proofed to be an effective treatment compared to enalapril in reducing heart failure hospitalisations and mortality in patients with severe "Heart failure with reduced ejection fraction" (HFREF). Recent European cardiology guidelines attributed a class IB recommendation for Sacubitril / Valsartan in HFREF patients who remain symptomatic despite optimal treatment with ACE-I, a beta-blocker, and a mineralocorticoid receptor antagonist. There is a significant overlap between diabetic and HFREF patients and thus, efficacy assessment of Sacubitril / Valsartan is a clinically meaningful issue in the large subgroup of HFREF patients with diabetes...
October 2016: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27818783/plasma-calcidiol-calcitriol-and-parathyroid-hormone-and-risk-of-new-onset-heart-failure-in-a-population-based-cohort-study
#20
Laura M G Meems, Frank P Brouwers, Michel M Joosten, Hiddo J Lambers Heerspink, Dick de Zeeuw, Stephan J L Bakker, Ron T Gansevoort, Wiek H van Gilst, Pim van der Harst, Rudolf A de Boer
BACKGROUND: Heart failure (HF) is a major problem in the Western world, with increasing prevalence and incidence. Because HF cannot be cured, prevention of HF is of utter importance. Calcidiol, calcitriol, and parathyroid hormone (PTH) have been identified as risk factors for cardiovascular disease. However, their association with new onset HF remains to be established. We investigated whether calcidiol, calcitriol, and PTH could be used to identify those subjects at risk for new onset HF, and if they had additive predictive value over established risk predictors like N-terminal-pro Brain-type natriuretic peptide and highly sensitive Troponin-T...
September 2016: ESC Heart Failure
keyword
keyword
71067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"